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Signaling by members of the TGFb family is much
dependent on the common-mediator Smad4, which
forms transcriptionally active complexes with all re-
ceptor-activatedSmads (R-Smads). Newfindingsdem-
onstrate that transcriptional intermediary factor 1g
(TIF1g) also can bind to R-Smads, as an alternative to
Smad4, and mediate different transcriptional effects.
The discovery of Smad molecules more than ten years
ago represented a breakthrough in our understanding
of the mechanism of signaling by members of the trans-
forming growth factor-b (TGFb) family. A strikingly simple
signaling scenario has since emerged; activation of
serine/threonine kinase receptors causes phosphoryla-
tion of receptor-activated Smads (R-Smads; Smad2
and 3 for signaling via TGFb, activin, and nodal recep-
tors; Smad1, 5 and 8 for signaling via bone morphoge-
netic protein [BMP], growth and differentiation factor
[GDF] and anti-Mu¨llerian hormone receptors), which then
form complexes with the common-mediator Smad4 and
regulate the transcription of specific genes (Massague´
et al., 2005). In this scenario, Smad4 has had a central
role, being involved in both arms of R-Smad signaling.
Interestingly, He et al. (2006) now present evidence that
R-Smads can partner not only with Smad4, but also
with transcriptional intermediary factor-1g (TIF1g; also
called Ectodermin, TRIM33, RFG7, and PTC7), thus dem-
onstrating that Smad signaling may be more diversified
than previously thought.
He et al. (2006) identified TIF1g as a protein which
bound to immobilized Smad2 and Smad3 in which the
C-terminal serine residues phosphorylated by receptors
had been mutated to aspartic acid residues to mimic
activation. In vivo interaction experiments verified that
binding occurred between TIF1g and Smad2 or 3 only
after TGFb stimulation. Moreover, little binding to wild-
type or mutated Smad1 was observed. Thus, the interac-
tion with TIF1g is specific for Smad2 and 3 and is strictly
dependent on activation by TGFb stimulation. Impor-
tantly, TIF1g and Smad4 were shown to compete for
binding to activated Smad2 and 3; thus the relative levels
of TIF1g and Smad4 in cells stimulated by TGFb are likely
to determine which binding partner the activated
R-Smads will have. Both TIF1gand Smad4 areubiquitous
molecules. For the understanding of Smad signaling, it
will thus be important to determine the mechanisms
whereby the levels of Smad4 and TIF1g are regulated.
What is then the functional consequence of forming
one Smad complex or the other? He et al. studied hema-
topoietic differentiation to explore this issue. TGFb has
a well-documented growth inhibitory effect in most
cell types, including hematopoietic precursor cells,
which depends on the R-Smad/Smad4 complex, and in-
volves, e.g., induction of the cell cycle inhibitor p21.
However, TGFb also induces erythroid differentiation
of hematopoietic cells, and He et al. could show thatthis effect is mediated by the R-Smad/TIF1g complex
(Figure 1). An important future task will be to elucidate
the transcriptional targets of this complex that mediate
the effect on erythroid differentiation.
The TIF1g protein contains several different domains.
In the N terminus there is an RBCC unit, consisting of
Figure 1. Novel Roles of TIF1g/Ectodermin in TGFb Signaling and
TIF1g’s Structure-Function
(A) Novel roles of TIF1g/Ectodermin in TGFb signaling. TGFb acti-
vates the type II (RII) and type I (RI) receptor serine/threonine
kinases that phosphorylate R-Smads and activate other signaling
pathways (Rho GTPases, phosphoinositide-30-kinase [PI3K] and
mitogen activated protein kinases [MAPK]). Phosphorylated
R-Smads make complexes with Smad4 as they enter in the nucleus.
The integrated signals from non-Smad effectors and active Smad
complexes with other transcription factors (TF), regulate transcrip-
tion of several genes. Such pathway-regulated gene programs (or-
ange circular nodes) play important roles in the control of prolifera-
tion and differentiation during embryonic mesoderm induction and
epidermal differentiation. TIF1g/Ectodermin interacts with phos-
phorylated R-Smads leading to erythrocyte differentiation via un-
known gene targets (red circular node). TIF1g/Ectodermin also inter-
feres with Smad4 function and thus inhibits TGFb superfamily
signals that mediate mesodermal and epidermal differentiation in
embryos and inhibition of proliferation in human cells.
(B) A diagrammatic sketch of TIF1g’s structure-function is shown,
including its 7 distinct domains and their corresponding known or
proposed functions.
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686a RING domain, B boxes, and a coiled-coil domain, and
in the C terminus there are a PHD domain and a bromo-
domain (Figure 1; Venturini et al., 1999). The interactions
with activated Smad2 and 3 occur via the sequence in
the middle of these regions, which is less well con-
served, explaining why the other three members of the
TIF1 family do not interact with Smads. RING domains
often have ubiquitin ligase activity, prompting the ques-
tion of whether TIF1g is involved in ubiquitination
events. In fact, the Xenopus counterpart of TIF1g, Ecto-
dermin, as well as human TIF1g, were shown by Dupont
et al. (2005) to bind and ubiquitinate Smad4 and thereby
control its activity. Ectodermin/TIF1g has a crucial role
for the specification of the ectoderm by restricting the
mesoderm-inducing activity of nodal as well as the
epidermal-inducing activity of BMP, thus favoring ecto-
dermal pluripotency until gastrulation and neural induc-
tion. Moreover, Ectodermin/TIF1g appears to be needed
to limit the TGFb-induced growth arrest response in
mammalian epithelial cells (Dupont et al., 2005).
While the studies by He et al. (2006) and Dupont et al.
(2005) both demonstrate roles for TIF1g/Ectodermin in
the control of differentiation by TGFb, the two studies dif-
fer with regard to the proposed mechanism; according
to He et al., TIF1g competes with Smad4 for binding to
receptor-activated R-Smads thus forming different
transcriptional complexes without affecting the Smad4
level, whereas according to Dupont et al., TIF1g/Ecto-
dermin is an inhibitor of Smad4 functions in TGFb and
BMP signaling pathways (Figure 1). The two models
are not mutually exclusive, and it is possible that in differ-
ent cellular contexts (epithelial or embryonic cells versus
hematopoietic precursors) one of them may dominate.
Of crucial importance for the understanding of the pre-
cise mechanism whereby TIF1g/Ectodermin functions,
will be to clarify if its ubiquitin ligase activity acts on com-
ponents in the TGFb signaling pathway and, if so, which
type of ubiquitination it induces, i.e.degradative polyubi-
quitination via Lys48-linked ubiquitin chains, or modu-
latory ubiquitination, e.g. via monoubiquitination or
Lys63-linked polyubiquitination. Indeed, it is tempting
to speculate that the lack of major effects on Smad4 sta-
bility reported by He et al. reflects that TGF1g/Ectoder-
min-induced ubiquitination of Smad4 leads to Smad4
degradation only after the action of additional ubiquitin
ligases, several of which have been shown to act on
Smad4 (More´n et al., 2005; Wan et al., 2004). Such a sce-
nario would set the stage for a shift in the ratio between
nuclear TIF1g and Smad4 and, ultimately, to Smad4-in-
dependent responses by the TIF1g-Smad2/3 complex.
Analyses of the effect of TGFb on the transcriptional
profiles of cells depleted of Smad4 have revealed that,
whereas most of the TGFb effects are blunted in such
cells, certain genes can be induced in the absence of
Smad4. Moreover, knock-out of Smad4 in mouse (Sir-
ard et al., 1998) or Drosophila (Wisotzkey et al., 1998),
has shown that Smad4 is not absolutely essential for
TGFb signaling. These findings can be partly explained
by the fact that TGFb also induces non-Smad pathways,
including Erk, JNK and p38 MAP kinase pathways,
phosphatidylinositol-30-kinase, PP2A phosphatase and
Rho GTPases (Figure 1; Moustakas and Heldin, 2005).
The findings of He et al. have now added another possi-
bility, i.e. that R-Smad/TIF1g complexes can mediatetranscriptional effects in the absence of Smad4. As
TIF1g has been shown to have an intrinsic transcriptional
inhibitory effect once tethered to a promoter (Venturini
et al., 1999), the possibility exists that R-Smads promote
hematopoietic differentiation by TIF1g-induced repres-
sion on certain gene promoters. In this light, it will be par-
ticularly interesting to explore which interactions the
coiled-coiled domain, PHD, and bromodomain mediate.
Smad complexes regulate transcription in cooperation
with other transcription factors, coactivators and core-
pressors in the nucleus. In fact, more than 60 nuclear
proteins have been shown to interact with Smad mole-
cules (Feng and Derynck, 2005). The He et al. study now
expands the number of interactions Smad complexes
can have with other nuclear proteins. Interesting ques-
tions,which remain tobeanswered, arewhether additional
analogous Smad2 and 3 binding proteins exist, whether
BMP R-Smads also can form transcriptional complexes
with molecules that, similar to TIF1g, replace Smad4, and
whether TIF1g regulates processes of differentiation
beyond hematopoiesis and germ layer specification.
The study by He et al. also opens up a number of other
questions to be answered. For instance, R-Smads and
Smad4 shuttle between the cytoplasm and the nucleus,
whereas TIF1g resides constitutively in the nucleus.
Thus, it will be important to clarify where the different
Smad complexes are formed. Is there a mechanism
whereby activated R-Smads upon entering the nucleus
are preferentially directed to TIF1g, or is there a mecha-
nism to replace Smad4 bound to R-Smads with TIF1g in
the nucleus, and if so, how is the exchange promoted?
The stage is now set for further important insights into
Smad signaling mechanisms, which are likely to come
in the near future.
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